INTRODUCTION
During recent studies performed on mouse bone marrow sections after Colcemid (Ciba Pharmaceutical Company, Summit, N. J.) administration, an increase in marrow megakaryocytes was observed (1).
This was of particular interest, since the increase in megakaryocytes was observed at a time when the immature nucleated cells and mature granulocytes were decreasing in number.
The chromosomal complement of morphologically recognizable megakaryocytes is tetraploid or greater (2, 3) , and these cells are thought to increase their ploidy through one or more rounds of endoreduplicative DNA synthesis before cytoplasmic maturation (4) (5) (6) . Presumably the earliest recognizable mega-karyocyte arises through the endoreduplication of an unrecognizable diploid precursor. While Colcemid and related colchicine derivatives are well known for their ability to arrest cells in metaphase, they also induce endoreduplication and polyploidy in a variety of plant and animal tissues after release from metaphase block (7) (8) (9) (10) . Could it be that it is this endoreduplication promoting property of Colcemid that leads to an increase in marrow megakaryocytes?
The periwinkle alkaloids, vincristine and vinblastine, differ structurally from colchicine and its derivatives but share with them the ability to arrest cells in metaphase. Soon after the introduction of the periwinkle alkaloids into clinical medicine, a thrombocytosis was noted in some patients (11, 12) . Vincristine and vinblastine have since been shown to have a therapeutic effect in thrombocytopenias of varying etiologies (13) (14) (15) (16) . Although immunosuppression (14, 17) and alterations in platelet release (18) have been suggested as possible underlying mechanisms, laboratory investigations have suggested that the thrombocytosis was secondary to an increase in marrow production, resulting from an increase in number, size, and ploidy of megakaryocytes (19) (20) (21) (22) (23) (24) (25) .
The vincristine induced thrombopoietic response is dose dependent. The most pronounced thrombocytosis is observed at doses close to the minimum dose required to produce an effect. At higher doses a biphasic response is observed; the thrombocytosis is preceeded by an early thrombocytopenia (26) (27) (28) .
These considerations prompted us to study the ef fects of Colcemid on mouse bone marrow and peripheral blood cells in relation to dosage and schedule of administration. The results of these studies are reported in this paper.
METHODS
Male National Institutes of Health all purpose white laboratory mice weighing 20-25 g were used in these experiments. Mice were given Colcemid intraperitoneally (i.p.) according to the following schecules: Group I, 2 Peripheral blood samples from treated mice were obtained at intervals during and after Colcemid administration. Peripheral blood was collected from the subelavian artery and vein after amputation of the left forelimb of mice anesthetized with sodium pentobarbital. Platelets were counted by the phase contrast method of Brecher et al. (29) . Erythrocytes and leukocytes were counted by using a model F Coulter counter. Leukocyte differentials were obtained from 100 cells in Wright-Giemsa stained smears from each animal. Reticulocyte counts were done on smears stained with brilliant cresyl blue; 1,000 erythrocytes were counted for each animal at each time point. Values for peripheral blood samples were obtained from 30 untreated control mice and from 5 mice at each experimental time point.
For the bone marrow studies, schedules I and IV were compared with untreated controls. Mice were anesthetized with sodium pentobarbital and were sacrificed by perfusion fixation at intervals as described previously (30) . Five mice were sacrificed at each time point. Both femurs were removed and decalcified in 10%o EDTA for seven days. 5 ,um transverse histologic sections were prepared from the femur at midshaft and stained by a modification of the Feulgen technique.
In previous studies megakaryocytes were enumerated within an 80 ,um wide sampling band which spanned the marrow section and passed through its center (1, 31) . While this sampling method was well suited for the enumeration and spatial localization of mitoses and mononuclear cells, it was not ideal for the evaluation of megakaryocytes since the sampling band included only a fraction of the megakaryocytes present in the marrow section (5-7 megakaryocytes per sampling band as compared with 30-50 megakaryocytes per marrow section). In the present study, megakaryocytes were counted over the entire marrow section in 20-40-sections on each schedule at each time point. Histologic sections counted from the same femur were separated by at least 50 ,um. The number of megakaryocytes in each section was normalized with respect to total marrow section cellular area. Since the marrow sections and central sinus were nearly circular, or approximated ellipses in shape, the cellular marrow area, 
RESULTS
Drug toxicity. At least 70 animals were represented in each of the experimental groups. There were no deaths in the uninjected controls or in Groups II and III during the 2-wk study period. Two mice in Group I died within 36 h of injection, and one mouse in Group IV died on day 10. It is doubtful that these were drug related deaths. Mild diarrhea and reduced oral intake were noted in all groups during the first 24-h after Colcemid administration.
Colcemid effects on the marrow. In Group I (Colcemid 2 mg/kg, single injection), the number of megakaryocytes/mm2 changed little during the first 8 h (Fig. 1A) . A A fall in marrow cellularity was observed in both Groups I and IV, beginning with the 4-h time point, and reaching a nadir at 24 h. At 24 h marrow cellularity fell to 66% of control values in Group I, and 37% of controls in Group IV, as previously described (1) . In Group I, total marrow cellularity retumed to control values by 48 h. In Group IV total marrow cellularity was restored by day four. Thus, the early rise in megakaryocytes occurred at a time when total marrow cellularity was falling in both groups. The large rise in megakaryocytes in Group IV coincided temporally with the recovery in total marrow cellularity.
Colcemid effects on peripheral blood cells. The effects of Colcemid dosage and schedule on the peripheral platelet count are shown in Fig. 2 . Thrombocytosis developed after Colcemid administration on all the schedules employed in this study. Thrombocytopenia was not observed in any of the experimental groups.
In Groups I and II an increase in peripheral platelet count was apparent between 12 and 24 h ( Fig. 2A and B). (Fig. 3) . In all groups the fall in leukocytes was apparent by 12 LA) and a corresponding rise in the peripheral platelet count at 24-48 h (Fig. 2A) . The early thrombopoietic response is most pronounced on the single 2 mg/kg dose (schedule I) and appears to be blunted in the presence of drug toxicity when the dose of Colcemid is increased or duration of drug exposure is prolonged. Thus, the early rise in marrow megakaryocytbs is much less pronounced on schedule IV (Fig.  1B) , and the corresponding rise in peripheral platelet count is also blunted on this schedule (Fig. 2D) . Blunting of the early rise in peripheral platelets is also evident on schedule II and III (Figs. 2B and 2C, respectively). It is evident from the time-course and dose response that the early thrombopoietic component is not a rebound phenomenon.
The early stimulatory effect of Colcemid is specific for megakaryocytes. The early rise in megakaryocytes occurs at a time when overall marrow cellularity is falling on both schedule I and on schedule IV. Similarly, on all drug schedules, the early rise in peripheral platelet counts at 24-48 h (Fig. 2 ), occurs at a time when the peripheral leukocyte counts (Fig.  3 ) and reticulocyte counts (Fig. 4) are falling.
In contrast, the late component appears to be a nonspecific reactive response to Colcemid's cytotoxicity and is demonstrated best on the most toxic Colcemid schedules. This component consists of a late rise in marrow megakaryocytes which is most clearly demonstrated on day three and four on schedule IV (Fig. 1B) . It coincides with the reactive restoration ofoverall marrow cellularity and is reflected in the peripheral platelet count between days 5 and 10. The late rise in platelet count is observable on all the schedules employed but is most distinct on schedules II and IV (Figs. 2B and 2D ). It coincides temporally with the reactive response observed in the circulating leukocytes (Figs. 3B-3D ) and reticulocytes (Figs. 4B-4D ). Other cytotoxic agents including cyclophosphamide, nitrogen mustard, cyto- (8) (9) (10) (11) (12) h) develops simultaneously with the release of cells from metaphase arrest. It is clear then that the increase in megakaryocytes could not have been due to an increase in the number of divisions of unrecognized precursors. Rather, the data suggest that Colcemid increases the rate of transition from precursor to megakaryocyte. Colchicine and its derivatives are known to induce endoreduplication and polyploidy in a variety of plant and animal cell systems (7) (8) (9) (10) . Detailed studies in colchicine treated cell populations have shown that newly formed tetraploid cells are derived from cells that had previously been arrested in metaphase (7, 8 (19) (20) (21) (22) (23) (24) (25) which has been attribuited to increased platelet produLction (19, 20, 22, 23) , secondary to an increase in marrow megakaryocytes (24) , and megakaryocyte endomitosis (20) . The biphasic dose response and the timecouirse of these changes are also similar to those observed with Colcemid (25) . The most pronounced thrombocytosis is observed with doses close to the minimutm dose requiired to prodtuce an effect (19) (20) (21) (22) (23) (24) (25) . However, at higher dosage an early thrombocytopenia is followed by a late reactive thrombopoietic response. As in the present stuidy, this late thrombopoietic response coincides with the restoration of over-all marrow celltularity (26, 27 (33) and other drtugs (34, 35) . These druigs may offer a variety of specific pharimiacologic probes for exploring the conditions that affect the precursor-megakaryocyte transition.
Quiite apart from their implications for the basic sttudy of thrombopoiesis, the similarities and differences between Colcemid and the vinca alkaloids may have certain cliniical implications as well. Vincristine and vinblastine have been found to raise the peripheral platelet couint in a wide variety of clinical thrombocytopenic puirpturas. Some investigators have suiggested that stuppression of the immtune response is the mechanism uinderlying the thrombocytosis (17) . This however, cannot explain the thrombocytosis indtuced in secondary thrombocytopenias or in patients with initially normal platelet counts. It is likely that the thrombopoiesis induced by Colcemid and the vinca alkaloids shares the same underlying mechanism. The biphasic dose response observed with both classes of agents suggests that the optimal thrombopoietic doses for the vinca alkaloids may be lower than doses ordinarily employed for cytolytic cancer therapy.
Furthermore, it would appear that vincristine's therapeutic index with respect to induction ofthrombocytosis may be lower than that of Colcemid. In laboratory animals the transition from maximum thrombocytosis to thrombocytopenia is observed over a twofold range of vincristine dosage (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . In contrast, in the present study thrombocytopenia was not observed over a sevenfold increase in Colcemid dosage.
In clinical practice the usefulness of vincristine is limited by its neurotoxicity, especially with prolonged administration. Colchicine and its derivatives lack neurotoxicity and exhibit few and relatively mild toxic effects in man even with prolonged exposure.
It is possible then, that colchicine and its derivatives may be more effective and less toxic clinical thrombopoietic agents than the vinca alkaloids.
